Pharmaceutical industry leaders increasingly understand the importance of health equity – both to improve health outcomes and accelerate growth. However, realizing measurable impact has proven challenging.
From discussions with industry leaders, we’ve identified three primary reasons for this disconnect. First, there is often a lack of leadership buy-in. Achieving meaningful outcomes requires health equity to be a top-down priority.
Insufficient support from management leads to a second problem: limited resources. Health equity initiatives require significant resources to engage diverse communities across the country at scale.
Without understanding the needs of underrepresented populations, these initiatives are destined to fail. And those communities aren’t monolithic. Black communities, for example, have unique challenges city by city. Detroit is different than Philadelphia, which is different than Los Angeles. And even in the same city, the challenges across different neighborhoods can vary substantially. The most effective way to manage these nuances is to employ a hyperlocal approach that accounts for the unique makeup and circumstances of each community.
Lastly, many companies lack a clear definition of their health equity goals. It is critical for pharmaceutical leaders to identify where they can make the most impact – whether it’s increasing the diversity of clinical trial participants or undertaking research on diseases that disproportionately impact marginalized communities. These leaders must rely on clear metrics to set measurable goals and track progress. Establishing a measurement framework is essential to ensure proper alignment and accountability.
Failure to execute health equity strategies poses bigger regulatory and reputational risks than ever for pharmaceutical companies. Policymakers, shareholders, and patient advocacy groups are scrutinizing corporate equity commitments. The 2023 omnibus spending bill now requires drug and device sponsors to submit “diversity action plans” designed to address the historic lack of diversity in clinical trials. The pressure for industry leaders to prioritize healthy equity will only mount – and those that fail to do so risk impeding the success of blockbuster drugs, slowing innovation, lowering employee morale, and incurring reputational damage.
Of course, this isn’t the only pressure leaders are facing – accelerating drug development and demonstrating value to investors also top the list. But it’s a mistake to view addressing health disparities as an issue that can be solved in the short term. Ensuring that more communities have access to the highest possible standard of health takes time and requires building trust. Organizations that take the long view and employ a thoughtful approach have a better chance to make a real impact.
We see five crucial ingredients to success.
Demands for health equity will only grow stronger. Communities want to see real change. Now is the time to deliver better health outcomes. Companies that put historically neglected communities at the center of their business goals can benefit not only reputationally as some have. They can also bring innovative discoveries and treatments to a larger market.